BRS201

BRS201 is an inhaled therapeutic agent composed of the secretome derived from human lung stem cells (LSC-SEC). Developed by Suzhou Bioray Biotech in collaboration with Shiyan Taihe Hospital, it is primarily investigated for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive fibrotic interstitial lung disease (PF-ILD). The secretome is a complex mixture of bioactive molecules, including exosomes, growth factors (such as HGF and VEGF), and cytokines, that exert anti-inflammatory, anti-fibrotic, and regenerative effects. BRS201 is designed to promote the repair of damaged alveolar epithelial cells and inhibit the activation of myofibroblasts by suppressing the TGF-β1/Smad signaling pathway, thereby slowing or reversing the progression of lung fibrosis. The drug is administered via inhalation to ensure direct delivery to the pulmonary tissue while minimizing systemic exposure.

Other names

Lung Stem Cell SecretomeLSC-ExoInhaled LSC-SECInhaled Lung Stem Cell Secretome